Susquehanna International Group, LLP Intra Cellular Therapies, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 27,140 shares of ITCI stock, worth $2.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,140

Previous 206,704 86.87%

Holding current value

$2.31 Million

Previous $14.2 Million 85.99%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $12.2 Million - $14.5 Million	-179,564 Reduced 86.87%	27,140 $1.98 Million
Q2 2024 Aug 15, 2024	BUY	$64.76 - $79.84 $10.3 Million - $12.7 Million	158,530 Added 329.08%	206,704 $14.2 Million
Q1 2024 May 07, 2024	SELL	$64.37 - $75.65 $6.35 Million - $7.46 Million	-98,617 Reduced 67.18%	48,174 $3.33 Million
Q4 2023 Feb 14, 2024	BUY	$46.37 - $73.65 $6.81 Million - $10.8 Million	146,791 New	146,791 $10.5 Million
Q2 2023 Aug 11, 2023	SELL	$54.67 - $66.44 $618,591 - $751,768	-11,315 Reduced 28.72%	28,088 $1.78 Million
Q1 2023 May 16, 2023	BUY	$43.8 - $56.99 $1.56 Million - $2.03 Million	35,564 Added 926.39%	39,403 $2.13 Million
Q4 2022 Feb 14, 2023	SELL	$44.07 - $54.45 $1.35 Million - $1.67 Million	-30,700 Reduced 88.89%	3,839 $203,000
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $1.27 Million - $1.78 Million	29,682 Added 611.12%	34,539 $1.61 Million
Q2 2022 Aug 15, 2022	SELL	$43.0 - $65.64 $55,126 - $84,150	-1,282 Reduced 20.88%	4,857 $277,000
Q1 2022 May 16, 2022	SELL	$38.74 - $62.09 $2.32 Million - $3.72 Million	-59,915 Reduced 90.71%	6,139 $376,000
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $5.25 Million - $7.97 Million	-149,117 Reduced 69.3%	66,054 $3.46 Million
Q3 2021 Nov 15, 2021	SELL	$28.72 - $42.49 $1.5 Million - $2.21 Million	-52,106 Reduced 19.5%	215,171 $8.02 Million
Q2 2021 Aug 11, 2021	BUY	$29.3 - $44.5 $1.2 Million - $1.83 Million	41,028 Added 18.13%	267,277 $10.9 Million
Q1 2021 May 17, 2021	BUY	$30.8 - $39.51 $449,372 - $576,450	14,590 Added 6.89%	226,249 $7.68 Million
Q4 2020 Feb 16, 2021	SELL	$23.34 - $32.22 $2.39 Million - $3.3 Million	-102,565 Reduced 32.64%	211,659 $6.73 Million
Q3 2020 Nov 16, 2020	BUY	$17.61 - $31.86 $1.28 Million - $2.31 Million	72,502 Added 29.99%	314,224 $8.06 Million
Q2 2020 Aug 14, 2020	SELL	$14.35 - $26.64 $648,289 - $1.2 Million	-45,177 Reduced 15.75%	241,722 $6.21 Million
Q1 2020 May 15, 2020	BUY	$12.31 - $33.12 $3.45 Million - $9.27 Million	279,931 Added 4017.38%	286,899 $4.41 Million
Q4 2019 Feb 14, 2020	SELL	$7.26 - $38.49 $243,725 - $1.29 Million	-33,571 Reduced 82.81%	6,968 $239,000
Q3 2019 Nov 14, 2019	BUY	$7.47 - $14.03 $155,413 - $291,894	20,805 Added 105.43%	40,539 $303,000
Q2 2019 Aug 16, 2019	SELL	$10.65 - $14.29 $834,885 - $1.12 Million	-78,393 Reduced 79.89%	19,734 $256,000
Q3 2018 Nov 14, 2018	SELL	$17.77 - $22.9 $474,441 - $611,407	-26,699 Reduced 21.39%	98,127 $2.13 Million
Q2 2018 Aug 14, 2018	SELL	$17.33 - $23.4 $460,596 - $621,925	-26,578 Reduced 17.55%	124,826 $2.21 Million
Q1 2018 May 15, 2018	BUY	$15.16 - $25.49 $709,760 - $1.19 Million	46,818 Added 44.77%	151,404 $3.19 Million
Q4 2017 Feb 14, 2018	SELL	$14.27 - $16.79 $14.3 Million - $16.8 Million	-1,000,441 Reduced 90.54%	104,586 $1.51 Million
Q3 2017 Nov 14, 2017	BUY	$10.77 - $22.1 $11.9 Million - $24.4 Million	1,105,027	1,105,027 $17.4 Million

Others Institutions Holding ITCI

# of Institutions

377

Shares Held

84.1M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.05B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Intra Cellular Therapies, Inc. Transaction History